These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32515018)

  • 21. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of CGRP in Migraine.
    Edvinsson L
    Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy.
    Scuteri D; Corasaniti MT; Tonin P; Nicotera P; Bagetta G
    J Headache Pain; 2021 Jul; 22(1):87. PubMed ID: 34330208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis.
    Hou M; Luo X; He S; Yang X; Zhang Q; Jin M; Zhang P; Li Y; Bi X; Li J; Cheng C; Xue Q; Xing H; Liu Y
    J Headache Pain; 2024 Jul; 25(1):116. PubMed ID: 39030528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The preclinical discovery and development of atogepant for migraine prophylaxis.
    Baraldi C; Beier D; Martelletti P; Pellesi L
    Expert Opin Drug Discov; 2024 Jul; 19(7):783-788. PubMed ID: 38856039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CGRP-targeted medication in chronic migraine - systematic review.
    Oliveira R; Gil-Gouveia R; Puledda F
    J Headache Pain; 2024 Apr; 25(1):51. PubMed ID: 38575868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine.
    Caronna E; Starling AJ
    Neurol Clin; 2021 Feb; 39(1):1-19. PubMed ID: 33223077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
    Yuan H; White CS; Silberstein SD
    Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.
    Al-Hassany L; Goadsby PJ; Danser AHJ; MaassenVanDenBrink A
    Lancet Neurol; 2022 Mar; 21(3):284-294. PubMed ID: 35093196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.
    Mathew PG; Klein BC
    Headache; 2019 Sep; 59(8):1421-1426. PubMed ID: 31318457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
    Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
    J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.
    Han L; Liu Y; Xiong H; Hong P
    Brain Behav; 2019 Feb; 9(2):e01215. PubMed ID: 30656853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L
    Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
    Do TP; Al-Saoudi A; Ashina M
    Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.
    Lee S; Staatz CE; Han N; Baek IH
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1365-1376. PubMed ID: 35729340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST; Wu JW
    Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.